scPharmaceuticals Inc.’s (SCPH) supplemental New Drug Application seeking to expand the indication of its lead product, Furoscix, to include treatment of edema due to fluid overload in patients with chronic kidney disease is under review by the FDA, with a decision due on March 6, 2025.Furoscix, a proprietary formulation of furosemide delivered via an On-Body Infusor, received its initial FDA approval in October 2022, for the treatment of congestion due to fluid overload in adults with New York Heart Association (NYHA) Class II/III chronic heart failure. In August 2024, the U.S. regulator expanded the indication of Furoscix, allowing for its use in NYHA Class IV chronic heart failure patients.Preliminary unaudited full-year 2024 FUROSCIX net revenue is expected to be in the range of $36.2 million to $36.5 million, representing 167% growth over the full year 2023 at the mid-point of the range.SCPH closed Wednesday’s (Mar.5, 2025) trading at $3.18, down 3.34%.Updated on Mar.7, 2025: FDA approved the sNDA for FUROSCIX to expand the indication to include treatment of edema in patients with chronic kidney disease on Mar.6, 2025